MARKET

IPA

IPA

Immuno Antib
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.26
-0.23
-3.54%
Closed 16:00 01/14 EST
OPEN
6.79
PREV CLOSE
6.49
HIGH
6.79
LOW
6.20
VOLUME
28.38K
TURNOVER
1.18M
52 WEEK HIGH
19.00
52 WEEK LOW
5.03
MARKET CAP
121.63M
P/E (TTM)
-10.0643
1D
5D
1M
3M
1Y
5Y
Investors in ImmunoPrecise Antibodies (CVE:IPA) have made a impressive return of 113% over the past three years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
Simply Wall St. · 21h ago
ImmunoPrecise Antibodies Announces Grant of Stock Options
VICTORIA, British Columbia, January 11, 2022--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 7, 2022 its board of directors approve...
Business Wire · 5d ago
ImmunoPrecise Antibodies board approves stock options grant
ImmunoPrecise Antibodies (NASDAQ:IPA) board approved the grant of 28,250 stock options under its stock option plan to acquire up to 28,250 shares. Each of the three non-executive directors of IPA re-elected at
Seekingalpha · 01/03 21:22
BRIEF-Immunoprecise Antibodies And Chempartner Biologics Announce Polytope TATX-03 Antibody Cocktail Manufacturing Collaboration
reuters.com · 12/20/2021 13:21
ImmunoPrecise Antibodies And ChemPartner Biologics Announce PolyTope TATX-03 Antibody Cocktail Manufacturing Collaboration
IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ:IPA) (TSXV:IPA) and ChemPartner Biologics Co. Ltd. ("ChemPartner") today announced their global antibody manufacturing
Benzinga · 12/20/2021 13:18
ImmunoPrecise Antibodies reports FQ2 results
ImmunoPrecise Antibodies (NASDAQ:IPA): FQ2 net loss of C$5.0M compared to net loss of C$0.46M for the three months ended October 31, 2020. Revenue of C$4.7M (-0.7% Y/Y) Press Release Adjusted EBITDA
Seekingalpha · 12/13/2021 13:22
BRIEF-Immunoprecise Reports Quarterly Revenue Of $4.7 Million
reuters.com · 12/13/2021 13:11
ImmunoPrecise Antibodies Q2 Sales $4.70M
ImmunoPrecise Antibodies (NASDAQ:IPA) reported $4.70 million in sales this quarter.
Benzinga · 12/13/2021 13:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IPA. Analyze the recent business situations of Immuno Antib through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IPA stock price target is 12.21 with a high estimate of 12.21 and a low estimate of 12.21.
High12.21
Average12.21
Low12.21
Current 6.26
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.31M
% Owned: 6.75%
Shares Outstanding: 19.43M
TypeInstitutionsShares
Increased
10
224.23K
New
10
204.89K
Decreased
3
91.91K
Sold Out
7
464.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.04%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Non-Executive Chairman/Independent Director
James Kuo
President/Chief Executive Officer/Director
Jennifer Bath
Chief Financial Officer
Lisa Helbling
Chief Scientific Officer
Ilse Roodink
Vice President/Director of Marketing
Carla Dahl
Vice President
Barry Duplantis
Other
Stefan Lang
Independent Director
Paul Andreola
Independent Director
Robert Burke
Independent Director
Brian Lundstrom
Independent Director
Gregory Smith
No Data
  • All
  • Financials
  • Insiders
No Data
About IPA
ImmunoPrecise Antibodies Ltd. is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

Webull offers kinds of Immunoprecise Antibodies Ltd stock information, including NASDAQ:IPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPA stock methods without spending real money on the virtual paper trading platform.